Armaviscon 1% syringe 2 ml, 2 pcs.

Area of application – orthopedics, rheumatology, traumatology, surgery, sports medicine. Armaviscon is a joint synovial fluid protector. It is used against the background of degenerative changes of synovial cartilage surface to improve joint mobility, decrease pain syndrome, decrease inflammatory reactions and restore homeostasis in cartilage.

Properties and efficacy

The product has analgesic, corrective action on bone and cartilage metabolism. Armaviscon is a sterile viscous solution of sodium salt of hyaluronic acid (sodium hyaluronate) with a high degree of purification, with a high molecular weight.

Hyaluronic acid is an essential component of extracellular matrix, present in high concentrations in cartilage and synovial fluid. Hyaluronic acid provides viscosity and elasticity of synovial fluid and is necessary for cartilage formation. In case of osteoarthritis there is a deficiency and qualitative changes of hyaluronic acid in synovial fluid and cartilage composition.

Intra-articular injection of hyaluronic acid leads to improvement of the functional state of the joint. When using Armaviscon in osteoarthritis of the knee joints improvement of clinical course is observed up to 6 months after application, anti-inflammatory and analgesic effect due to replenishment of the volume and restoration of viscosity and elasticity of synovial fluid that fills the joint cavity and acts as intra-articular lubricant.

It prevents friction of the articular surfaces, thus eliminating pain and inflammation. It also protects against premature wear and destruction of hyaline cartilage, ensures mobility and has cushioning properties (absorbs external blows protecting the joint components from damage).

The solution of sodium hyaluronate is distributed locally in the joint cavity, where it undergoes local transformation with its lubricating effect. Extraction or replacement of the product is not applicable, as it is inseparably mixed with the synovial fluid of the joint.

Indications

To increase joint mobility and eliminate pain caused by degenerative-dystrophic or post-traumatic changes in the joints;
for rehabilitation after arthroscopy;
for the treatment of patients who have increased physical activity and regularly load the affected joint.

Pharmacological effect

Area of ​​application: orthopedics, rheumatology, traumatology, surgery, sports medicine. Armaviscon is a protector of joint synovial fluid. It is used against the background of degenerative changes in the surface of synovial cartilage to improve joint mobility, reduce pain, reduce inflammatory reactions and restore homeostasis in the cartilage.

Properties and efficiency

The drug has an analgesic and corrective effect on the metabolism of bone and cartilage tissue. Armaviscon is a sterile viscous solution of the sodium salt of hyaluronic acid (sodium hyaluronate) of high purity, high molecular weight.

Hyaluronic acid is an essential component of the extracellular matrix and is present in high concentrations in cartilage and synovial fluid. Hyaluronic acid provides viscosity and elasticity to synovial fluid, and is also necessary for the formation of cartilage. In osteoarthritis, there is a deficiency and qualitative changes in hyaluronic acid in the composition of synovial fluid and cartilage.

Intra-articular injection of hyaluronic acid leads to an improvement in the functional state of the joint. When using Armaviscon for osteoarthritis of the knee joint, there is an improvement in the clinical course of osteoarthritis up to six months from the date of use, an anti-inflammatory and analgesic effect is observed due to replenishment of the volume and restoration of the viscosity and elasticity of the synovial fluid, which fills the joint cavity and acts as an intra-articular lubricant.

It prevents friction of the articular surfaces, which eliminates pain and inflammation. It also protects against premature wear and destruction of hyaline cartilage, ensures mobility, and has shock-absorbing capabilities (absorbs external shocks, protecting joint components from damage).

The sodium hyaluronate solution is distributed locally into the joint cavity, where it undergoes local transformations, providing a lubricating effect. Removing or replacing the product is not applicable, since it is inseparably mixed with the synovial fluid of the joint.

Special instructions

Sodium hyaluronate is obtained by fermentation of Streptococcus equi bacteria and is carefully purified. However, the physician must consider the potential risks associated with injecting any biological substance.

Extra-articular administration of Armaviscon into the joint capsule or synovial tissue is not allowed. This may cause local side effects. It is unacceptable for the product to enter blood vessels.

During the first 2 days after the procedure, it is recommended not to overload the joint, especially prolonged loading should be avoided. Armaviscon does not affect a person’s ability to drive vehicles or engage in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions. Patients with inflammatory diseases, in particular with ankylosing spondylitis and rheumatoid arthritis, are not prescribed Armaviscon.

Not intended for children. For single use only. The kit may include 2 disposable sterile injection needles so that the doctor can select a needle of the required size depending on the joint into which the product will be injected. To ensure safe use and disposal of used needles, follow national and local regulations.

Composition

Per 1 ml: sodium hyaluronate – 9-11 mg/ml (1%), sodium chloride – 8.50 mg/ml, sodium hydrogen phosphate dihydrate – 0.28 mg/ml, sodium dihydrogen phosphate dihydrate – 0.044 mg/ml, water for injection – up to 1 ml.

The dynamic viscosity of the solution is > 100 mPa s, osmolality – 250 – 350 mOsm/kg, pH – 6.5 – 7.5.

Contraindications

• hypersensitivity to the components of the product;

• presence of infection or damage to the skin in the injection area;

• acute synovitis;

• children under 18 years of age (due to lack of clinical data).

Side Effects

Moderate pain, swelling, increased temperature and redness in the injection area, and an increase in exudate in the joint cavity may occur. The above symptoms are transient and usually disappear after 24 hours. If these symptoms occur, it is recommended to unload the affected joint and apply ice.

Allergic reactions can occur extremely rarely.

Interaction

Armaviscon should not be prescribed concomitantly with other intra-articular injections due to the lack of significant experience.

Disinfectants containing quaternary ammonium compounds should not be used, since hyaluronic acid precipitates in the presence of these substances.

Action

Intra-articular. The contents of one filled syringe – 2 ml (20 mg) should be injected into the knee joint once a week, in a course of 5 injections according to the standard method described below. Typically a 1.5″ 21G needle is used for the knee joint; for other joints it is recommended to use the appropriate size needle (17G to 22G) depending on the joint.

Method of administration

The product should only be administered by medical personnel who have undergone special training. The mode of administration to the hip and other joints is determined by the doctor individually, taking into account the severity of degenerative or traumatic changes in the joint.

It is recommended to perform injections into the hip and other joints under ultrasound or fluoroscopic control. It is recommended to warm the product to room temperature before use.

The product should be injected exactly into the joint cavity using standard methods, taking into account the anatomical features. Before administering the product, effusion from the joint capsule should be removed. The same needle can be used to remove the effusion and administer the agent, inserted once before aspiration.

In this case, the syringe with the product is attached to the needle freed from the syringe. To confirm that the needle is in the joint cavity, an available amount of synovial fluid should be aspirated before inserting slowly.

The rules of asepsis and antisepsis should be observed when performing the procedure. The injection of the drug into the joint cavity should be stopped if pain occurs during the injection. When inserting a needle, especially for injections into the hip joint, the use of local anesthesia is recommended. Avoid getting air into the syringe.

Product that is not completely used cannot be stored. The duration of the therapeutic effect is up to 6 months. If necessary, it is possible to carry out a second course of injections after consultation with a doctor.

Storage conditions

Store at temperatures from + 2 °C to + 25 °C.

Do not freeze.

Keep out of the reach of children.

Shelf life

3 years. Do not use after the expiration date!

Manufacturer

Grotex LLC, Russia